Arh. farm 2025; 75: S12–S13 **IL 2**
https://doi.org/10.5937/arhfarm-62037

UNAPREĐENJE FARMACEUTSKIH INOVACIJA KROZ INSTITUCIONALNU TRANSFORMACIJU: SAIGE PROJEKAT U INSTITUTU ZA MEDICINSKA ISTRAŽIVANJA

Milica Zeković[1*], Ivana Drvenica[2]

[1]Grupa za ishranu i metabolizam, Institut za medicinska istraživanja, Institut od nacionalnog značaja za Republiku Srbiju, Univerzitet u Beogradu, Beograd, Srbija
[2]Grupa za imunologiju, Institut za medicinska istraživanja, Institut od nacionalnog značaja za Republiku Srbiju, Univerzitet u Beogradu, Beograd, Srbija

*milica.zekovic@imi.bg.ac.rs

Institut za medicinska istraživanja Univerziteta u Beogradu (IMI) od 2022. godine sprovodi proces institucionalne transformacije uz podršku projekta *Serbia Accelerating Innovation and Growth Entrepreneurship* (SAIGE), koji je usmeren na razvoj inovacione infrastrukture i jačanje kapaciteta za translaciju naučnih rezultata u društveno i komercijalno relevantne proizvode. Ključni strateški stubovi transformacije obuhvataju izvrsnost u nauci, razvoj ljudskih resursa, modernizaciju istraživačke infrastrukture i snažniji fokus na inovacije i transfer tehnologija. U okviru inovacionog portfolija IMI, posebno su od strane SAIGE podržani *Proof of Concept* (PoC) i *Cross-the-Gap in Technology Transfer and Commercialization* (CtG) projekti sa farmaceutskom i biomedicinskom relevantnošću, koji reflektuju različite paradigme translacione nauke i održivog razvoja. Razvoj stabilizovanih čvrstih formulacija hem-gvožđa iz nusproizvoda mesne industrije predstavlja model cirkularne bioekonomije i održive valorizacije bioloških resursa; platforma za rast ćelija pacijenata obolelih od multiplog mijeloma je korak ka personalizovanoj onkološkoj medicini; ekstrakti suvih semena novih sorti boba i organskim kalcijumom obogaćeni voćni sokovi doprinose inovacijama u oblasti funkcionalne hrane i dijetetskih suplemenata; *in-house* razvijeni ELISA testovi omogućavaju nova rešenja u kliničkoj dijagnostici, dok tkivni derivati placente otvaraju nove mogućnosti u razvoju 3D štampanih mukoadhezivnih filmova za regeneraciju oralnih tkiva. Ovi projekti ilustruju transformativni kapacitet IMI da kroz interdisciplinarni pristup i strateško upravljanje inovacijama integriše akademsku izvrsnost sa primenljivim rešenjima u oblasti savremenih farmaceutskih istraživanja i razvoja.

Zahvalnica

Rad je realizovan uz podršku projekta *Serbia Accelerating Innovation and Growth Entrepreneurship* (SAIGE), koji sprovodi Ministarstvo nauke, tehnološkog razvoja i inovacija Republike Srbije uz podršku Svetske banke.

https://doi.org/10.5937/arhfarm-62037

ADVANCING PHARMACEUTICAL INNOVATION THROUGH INSTITUTIONAL TRANSFORMATION: THE SAIGE PROJECT AT THE INSTITUTE FOR MEDICAL RESEARCH

Milica Zeković[1*], Ivana Drvenica[2]

[1]Group for Nutrition and Metabolism, Institute for Medical Research, National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia
[2]Group for Immunology, Institute for Medical Research, National Institute of the Republic of Serbia, University of Belgrade, Belgrade, Serbia

*milica.zekovic@imi.bg.ac.rs

Since 2022, the Institute for Medical Research, University of Belgrade (IMI), has been implementing an institutional transformation supported by the *Serbia Accelerating Innovation and Growth Entrepreneurship (SAIGE)* project, aimed at developing innovation infrastructure and strengthening the capacity for translating scientific results into socially and commercially relevant products. The key strategic pillars of transformation include scientific excellence, human resource development, modernization of research infrastructure, and a strengthened focus on innovation and technology transfer. Within the IMI innovation portfolio, the *Proof of Concept (PoC)* and *Cross-the-Gap in Technology Transfer and Commercialization (CtG)* projects supported through SAIGE reflect diverse paradigms of translational science and sustainable innovation. The development of stabilized solid formulations of heme-iron derived from meat industry by-products embodies the principles of circular bioeconomy and sustainable bioresource valorization; the platform for the growth of multiple myeloma patient-derived cells marks a step toward personalized oncology; extracts from new faba bean varieties and organically calcium-enriched fruit juices contribute to advances in functional food and dietary supplement innovation; in-house developed ELISA tests provide novel solutions in clinical diagnostics, while placenta-derived tissue derivatives open new avenues in the design of 3D-printed mucoadhesive films for oral tissue regeneration. These projects illustrate the Institute's transformative capacity to integrate academic excellence with practical innovation through interdisciplinary collaboration and strategic innovation management, bridging science and application in contemporary pharmaceutical research and development.

Acknowledgements

This work was supported by the Serbia Accelerating Innovation and Growth Entrepreneurship (SAIGE) project, implemented by the Ministry of Science, Technological Development and Innovation of the Republic of Serbia with the support of the World Bank.